Laurus Labs Limited (NSE:LAURUSLABS), a pharmaceuticals manufacturer, reported unaudited consolidated financial results for the quarter ended 30 June 2026 on 24 July 2026. The company's board approved a consolidated net profit of Rs 362.07 crore on total revenue of Rs 2,035.49 crore, representing growth from Rs 161.68 crore net profit and Rs 1,580.00 crore revenue in the same period of the prior year.
Key Highlights
- Consolidated net profit for Q1 FY27 stood at Rs 362.07 crore, up 124% year-on-year from Rs 161.68 crore in Q1 FY26.
- Total consolidated revenue increased to Rs 2,035.49 crore in Q1 FY27 from Rs 1,580.00 crore in Q1 FY26, a growth of 28.8% YoY.
- Consolidated profit before tax for the quarter was Rs 481.36 crore compared to Rs 224.22 crore in the prior year quarter, rising 114.7% YoY.
- Earnings per share on a basic and diluted basis stood at Rs 6.80 and Rs 6.80 respectively for Q1 FY27, up from Rs 3.02 in Q1 FY26.
- The board approved the unaudited results at a meeting held on 24 July 2026; statutory auditors Deloitte Haskins & Sells LLP issued an unmodified conclusion on the limited review.
- During the quarter, the company allotted 393,001 equity shares following the exercise of stock options by employees under the Employee Stock Option Scheme.
About the Company
Laurus Labs Limited (NSE:LAURUSLABS) is a pharmaceutical manufacturer headquartered in Hyderabad, Telangana, with registered office at Laurus Enclave, Parawada Mandal, Anakapalli District, Andhra Pradesh. The company manufactures and sells pharmaceuticals across multiple therapeutic segments and geographies. The consolidated financial results include operations from wholly owned subsidiaries Sriam Labs Private Limited, Laurus Holdings Limited (UK), Laurus Generics Inc (USA), Laurus Generics GmbH (Germany), Laurus Synthesis Private Limited, Laurus Generics SA (Pty) Ltd (South Africa), and Laurus Bio Private Limited (78.34% held), along with associates ImmunoAdoptive Cell Therapy Private Limited (34.89% held) and Ethan Energy India Private Limited (26.00% held), and joint venture KRKA Pharma Private Limited (49.00% held). The company is listed on the National Stock Exchange (NSE) and BSE.
Announcement in Detail
The board of directors of Laurus Labs Limited, at its meeting held on 24 July 2026 (commenced at 2:00 p.m. IST and concluded at 2:42 p.m. IST), approved the unaudited standalone and consolidated financial results for the quarter and half-year ended 30 June 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, Deloitte Haskins & Sells LLP, conducted a limited review of the consolidated financial results and issued an unmodified conclusion. The consolidated financial results show total income (revenue from operations plus other income) of Rs 2,035.49 crore for Q1 FY27 compared to Rs 1,580.00 crore in Q1 FY26. Revenue from operations specifically reached Rs 2,026.31 crore in Q1 FY27 versus Rs 1,569.57 crore in the prior year period.
On the expense side, the consolidated total expenses for Q1 FY27 were Rs 1,554.13 crore against Rs 1,355.78 crore in Q1 FY26. Cost of materials consumed rose to Rs 785.77 crore from Rs 599.41 crore year-on-year. Employee benefits expense increased to Rs 258.70 crore from Rs 214.80 crore, and other expenses were Rs 373.33 crore compared to Rs 335.29 crore. These increases were offset by the higher revenue base, resulting in improved profitability. Consolidated profit before tax jumped to Rs 481.36 crore from Rs 224.22 crore, while consolidated tax expense totalled Rs 119.37 crore (comprising current tax of Rs 134.88 crore and deferred tax benefit of Rs 15.51 crore). After accounting for share of net profit from associates and joint venture of Rs 0.08 crore, the consolidated net profit for Q1 FY27 was Rs 362.07 crore.
The company's consolidated other comprehensive income (net of tax) showed a loss of Rs 2.21 crore for Q1 FY27. Total consolidated comprehensive income for the quarter reached Rs 359.86 crore, with the full amount attributable to equity holders of the company. During the quarter, the company allotted 393,001 equity shares of face value Rs 2 each consequent to employee stock option exercises under the Employee Stock Option Scheme. The financial results are presented in accordance with Indian Accounting Standards (Ind AS) and prepared consistent with guidance issued by SEBI. The paid-up equity share capital as of 30 June 2026 was Rs 107.97 crore, with other equity of Rs 5,192.09 crore as reported in the consolidated balance sheet.
Impact on Investors
The strong profitability reported in Q1 FY27 reflects both revenue expansion and operational efficiency. Investors will note that consolidated net profit of Rs 362.07 crore represents a 124% increase year-on-year, outpacing the 28.8% growth in revenue. This margin expansion indicates improved operational leverage, with consolidated profit before tax rising 114.7% despite revenue growth of just 28.8%, suggesting cost management and higher-margin product mix contributions. Earnings per share increased substantially to Rs 6.80 from Rs 3.02 in the prior year period. The allotment of 393,001 equity shares during the quarter through employee stock option exercises represents a modest dilution; at the current share capital base of Rs 107.97 crore (representing approximately 540 million equity shares of face value Rs 2), this dilution is approximately 0.07% of issued share capital.
The filing shows that the company continues to operate through a diversified group structure including wholly owned manufacturing subsidiaries in India, the UK, USA, Germany, and South Africa, as well as associates and joint venture interests in emerging therapeutics and renewable energy sectors. The consolidated basis of reporting means results already incorporate these entities. Investors should note the pending Composite Scheme of Arrangement filed with the National Company Law Tribunal (NCLT), Amaravathi bench, which proposes the demerger of an identified business undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of the remaining undertaking with the parent company, with an appointed date of 1 April 2026. Until NCLT and other regulatory approvals are obtained, the consolidated financial results are presented without giving effect to this proposed restructuring, which may have material implications for future segment reporting and operational structure.
Sector / Market Context
The Indian pharmaceutical industry continues to be a significant contributor to the country's manufacturing and exports base. According to publicly available industry data, India produces approximately 10% of global pharmaceuticals by volume and exports to over 200 countries. Domestic pharmaceutical revenue has been growing in the mid-to-high single-digit percentage range annually, driven by rising healthcare expenditure, increased penetration of branded generics, and growing export volumes. Contract manufacturing and active pharmaceutical ingredient (API) production remain important segments within the Indian pharma market, with companies operating across global geographies to serve regulated and semi-regulated markets. The sector benefits from India's cost-competitive manufacturing base, regulatory expertise under SEBI and the Central Drugs Standard Control Organisation, and established export infrastructure. Companies like Laurus Labs with international operations in Europe and the USA are positioned to capture opportunities in regulated markets while maintaining domestic manufacturing capabilities.